Advertisement

Topics

Imugene Company Profile

00:00 EDT 22nd June 2018 | BioPortfolio

Imugene’s goal is to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines both locally and globally. Each new drug formulation being developed by Imugene addresses an unmet market need and uses well characterised molecules that have known and proven regulatory routes.

Imugene aims to develop and license a Vitamin D formulation using its platform technology Linguet™. Generic pharmaceutical products focusing on Parkinson’s Disease and over-the-counter pain relief markets are planned for later in 2014.

Imugene’s focus is on pushing early revenue generating products, rather than a classic drug delivery model that focuses on a single opportunity licensing deal far into the future. We are targeting pharmaceutical products that do not need significant clinical investment to gain regulatory approval. This ensures the most cost effective and most rapid path to market.

Linguet is targeted at those drugs which:

  • Show poor oral bioavailability (e.g. progesterone, testosterone)
  • Require rapid onset of action (e.g. analgesics, erectile dysfunction, acute seizure products)
  • Cause gastrointestinal irritation (e.g. NSAIDs, bisphosphonates & statins)
  • Are degraded in the gastrointestinal tract and require dose compensation (e.g. hormone replacement formulations)
  • Are adversely affected by high first-pass metabolism in the liver (a drug metabolism process where the drug is significantly reduced before it reaches the bloodstream) and thus rely on massive over dosing in order to deliver the correct therapeutic outcome (e.g. pain relief)

While the Linguet™ technology has potentially broad applications, Imugene has selected four priority targets initially:

  • Vitamin D
  • Parkinson’s Disease
  • Pain (NSAID)
  • Osteoporosis

Location

Suite 1, 1233 High Street
Armadale
VICTORIA
3143
Australia

Contact

Phone: +61 3 9824 5254
Fax: +61 3 9822 7735
Email: info@imugene.com


News Articles [1 Associated News Articles listed on BioPortfolio]

Imugene Ltd IMU Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15022018] Prices from USD $250

SummaryImugene Ltd Imugene is a clinical stage biopharmaceutical company which researches and develops vaccines in the area of immuneoncology. The company focuses on developing immunotherapies for the...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Imugene

Imugene’s goal is to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines both locally and globally. Each new drug formulation being deve...

More Information about "Imugene" on BioPortfolio

We have published hundreds of Imugene news stories on BioPortfolio along with dozens of Imugene Clinical Trials and PubMed Articles about Imugene for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Imugene Companies in our database. You can also find out about relevant Imugene Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record